@article{7f52d670c3f54d29a99938406d21916a,
title = "Chemoprevention of human skin cancers",
author = "Loescher, \{Lois J.\} and Meyskens, \{Frank L.\}",
note = "Funding Information: In humans, oral DFMO has resulted in severe dose-related toxicities (gastrointestinal, neurologic, and hematologic toxicities, fatigue, rash, arthralgias, alopecia, high frequency hearing loss), necessitating discontinuation of the drug.5{\textquoteright} It has also been known to cause teratogenesis and induce abortions in animals. Little is known about the toxicity of topical DFMO, but when administered to UVB-irradiated mice, the toxicity of topical DFMO was minimal (personal communication, H. Gensler, February 1990). A chemoprevention trial funded by the National Cancer Institute is underway at the University of Arizona Cancer Center using topical DFMO and vitamin E in human subjects with actinic keratoses.",
year = "1991",
month = feb,
doi = "10.1016/0749-2081(91)90054-S",
language = "English (US)",
volume = "7",
pages = "45--52",
journal = "Seminars in oncology nursing",
issn = "0749-2081",
publisher = "Elsevier Inc.",
number = "1",
}